In an intubated patient with organophosphorus poisoning who presents with tachycardia, blood pressure 120/80 mmHg, respiratory rate 30 breaths/min, SpO₂ 99 % and sudden loss of neck muscle tone, what is the appropriate management?

Immediate Management: Escalate Atropine and Administer Benzodiazepines

This patient is developing intermediate syndrome (IMS) with sudden loss of neck muscle tone—immediately increase atropine dosing to achieve full atropinization, administer benzodiazepines for CNS protection, and add pralidoxime if not already given. The tachycardia (pulse 145) with tachypnea (RR 30) despite intubation and adequate oxygenation (SpO₂ 99%) indicates inadequate atropinization, while sudden neck muscle weakness signals evolving nicotinic neuromuscular failure characteristic of IMS 1.

Understanding the Clinical Picture

Your patient presents with mixed cholinergic toxicity:

• Nicotinic excess: Tachycardia (145 bpm) and now sudden neck muscle weakness (loss of neck holding)
• Inadequate atropinization: Tachypnea (RR 30) despite mechanical ventilation suggests persistent bronchorrhea/bronchospasm
• Emerging IMS: Sudden loss of neck muscle tone 24+ hours post-exposure is the hallmark presentation of intermediate syndrome, which typically develops 2-4 days after exposure when acute cholinergic signs are resolving 2

Critical Action Steps

1. Aggressive Atropine Escalation (Class I, LOE A)

Double the atropine dose every 5 minutes until full atropinization is achieved 1, 3:

• Target endpoints: Clear chest on auscultation, heart rate >80 bpm, systolic BP >80 mmHg
• Your patient's tachycardia is a nicotinic effect, not a sign of adequate atropinization
• The respiratory rate of 30 despite intubation indicates ongoing bronchorrhea/bronchospasm requiring more atropine
• Patients often require 20-75 mg or more for severe poisoning 4
• Once stabilized, maintain with atropine infusion 1

Common pitfall: Mistaking nicotinic tachycardia for adequate atropinization—atropine targets muscarinic receptors and does NOT reverse the tachycardia or muscle weakness 1.

2. Immediate Benzodiazepine Administration (Class I, LOE C-LD)

Give diazepam (first-line) or midazolam immediately 1, 3:

• Prevents seizures and treats CNS effects of organophosphate toxicity
• Essential for preventing deterioration even without overt seizures
• The sudden loss of consciousness/muscle tone may represent subclinical seizure activity

3. Pralidoxime Administration (Class IIa, LOE A)

Administer pralidoxime if not already given 1, 3:

• Reactivates acetylcholinesterase enzyme, reversing nicotinic effects
• Time-critical: Must be given before "aging" of the organophosphate-enzyme complex occurs
• Slowly improves respiratory and skeletal muscle strength over hours to days
• The neck muscle weakness indicates nicotinic neuromuscular dysfunction that pralidoxime can address
• Continue even if already started—effects are gradual 3

Recognizing Intermediate Syndrome

Your patient is developing IMS, characterized by 2, 5:

• Onset 24-96 hours after exposure (after acute cholinergic phase resolves)
• Classic triad: Weakness of respiratory muscles (diaphragm, intercostals, neck muscles), proximal limb muscles, and cranial nerve-innervated muscles
• Occurs in ~20% of organophosphate poisoning cases
• Can progress from isolated neck weakness to complete respiratory failure
• Duration: Typically requires ventilatory support for 7-21 days

The sudden loss of neck holding is an early warning sign—this patient may progress to complete respiratory muscle paralysis requiring prolonged ventilation 2, 6.

Ventilator Management Considerations

Since the patient is already intubated:

• Avoid depolarizing muscle relaxants (succinylcholine, mivacurium)—Class III recommendation 1
• Use minimal doses of non-depolarizing relaxants only if absolutely necessary 2
• Monitor for worsening neuromuscular weakness requiring increased ventilatory support
• Prepare for prolonged ventilation (7-21 days typical for IMS) 2

Monitoring and Supportive Care

Essential monitoring:

• Continuous respiratory function assessment (arterial blood gases, ventilator parameters)
• Serial neurological examinations for progression of muscle weakness
• Fluid/electrolyte balance (profuse diarrhea common)
• Consider repetitive nerve stimulation studies if available—"decrementing response" confirms IMS 2, 6

Supportive measures:

• Maintain adequate nutrition
• Physiotherapy to prevent complications
• Prophylactic antibiotics NOT routinely indicated unless aspiration documented 2
• Monitor for ventilator-associated pneumonia given prolonged intubation risk 7

Why This Patient Needs Urgent Intervention

The combination of inadequate atropinization (tachypnea despite intubation) and emerging nicotinic failure (neck muscle weakness) creates a critical window for intervention:

• Early aggressive atropinization improves survival 1, 3, 4
• Pralidoxime is most effective before enzyme "aging" occurs 3
• IMS can progress rapidly from neck weakness to complete respiratory failure 2, 5
• Delays in recognizing and treating IMS increase mortality 2

The tachycardia should NOT reassure you—it reflects nicotinic excess, not adequate treatment. Focus on clearing secretions and preventing neuromuscular deterioration 1, 6.